$16.40
0.09[0.55%]
At close: Apr 26
$16.40
0[0.00%]
After Hours: 7:10PM EDT
ACADIA Pharmaceuticals
(NASDAQ:ACAD)Latest News for ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)
ACADIA Pharmaceuticals Stock (NASDAQ: ACAD)
Categories: All
Monday, April 22, 2024
Wednesday, April 17, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, March 25, 2024
Tuesday, March 19, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
- Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 12, 2024, 2:07PM
- Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30.19Benzinga Newsdesk - Mar 12, 2024, 2:04PM
- RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $30Benzinga Newsdesk - Mar 12, 2024, 10:41AM
- Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $37Benzinga Newsdesk - Mar 12, 2024, 9:25AM
- Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Mar 12, 2024, 9:17AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 12, 2024, 9:05AM
- Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Lowers Price Target to $19Benzinga Newsdesk - Mar 12, 2024, 8:14AM
- Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 12, 2024, 8:11AM
- Baird Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $31Benzinga Newsdesk - Mar 12, 2024, 8:00AM
- B of A Securities Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $30Benzinga Newsdesk - Mar 12, 2024, 7:26AM
- Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: DetailsVandana Singh - Mar 12, 2024, 7:19AM
- Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33Benzinga Newsdesk - Mar 12, 2024, 7:09AM
- JMP Securities Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $39Benzinga Newsdesk - Mar 12, 2024, 6:48AM
- HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $33 Price TargetBenzinga Newsdesk - Mar 12, 2024, 6:45AM
- Acadia Pharmaceuticals shares are trading lower after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.Benzinga Newsdesk - Mar 12, 2024, 6:44AM
- Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32Benzinga Newsdesk - Mar 12, 2024, 5:56AM
- ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAvi Kapoor - Mar 12, 2024, 5:36AM
- Mizuho Downgrades ACADIA Pharmaceuticals to Neutral, Lowers Price Target to $25Benzinga Newsdesk - Mar 12, 2024, 5:27AM
Monday, March 11, 2024
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Mar 11, 2024, 5:34PM
- Acadia Pharmaceuticals shares are trading lower after the company reported the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia did not meet the primary endpoint.Benzinga Newsdesk - Mar 11, 2024, 4:40PM
- ACADIA Pharmaceuticals Shares Resume TradeHappy Mohamed - Mar 11, 2024, 4:35PM
- Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga Newsdesk - Mar 11, 2024, 4:30PM
- Acadia Pharmaceuticals Announces Top-Line Results From Phase 3 ADVANCE-2 Trial Of Pimavanserin In Negative Symptoms Of Schizophrenia; Study Did Not Meet Primary EndpointBenzinga Newsdesk - Mar 11, 2024, 4:14PM
- ACADIA Pharmaceuticals Shares Halted, News PendingBenzinga Newsdesk - Mar 11, 2024, 4:01PM
- Trading Halt: Halted at 4:00:53 p.m. ET - Trading Halt: Halt News PendingBenzinga Newsdesk - Mar 11, 2024, 4:00PM
Friday, March 01, 2024
Wednesday, February 28, 2024
- HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $33 Price TargetBenzinga Newsdesk - Feb 28, 2024, 12:15PM
- Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $42 Price TargetBenzinga Newsdesk - Feb 28, 2024, 11:03AM
- RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $35Benzinga Newsdesk - Feb 28, 2024, 9:47AM
- Mizuho Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $39Benzinga Newsdesk - Feb 28, 2024, 8:42AM
- Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals StockBenzinga Insights - Feb 28, 2024, 7:00AM
- Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $36Benzinga Newsdesk - Feb 28, 2024, 6:22AM
Tuesday, February 27, 2024
- Acadia Pharmaceuticals Expects 2024 DAYBUE Net Product Sales Of $370M-$420M, NUPLAZID Net Product Sales Of $560M-$590MBenzinga Newsdesk - Feb 27, 2024, 4:55PM
- Recap: ACADIA Pharmaceuticals Q4 EarningsBenzinga Insights - Feb 27, 2024, 4:15PM
- ACADIA Pharmaceuticals Q4 2023 GAAP EPS $0.28 Misses $0.31 Estimate, Sales $231.04M Beat $223.79M EstimateBenzinga Newsdesk - Feb 27, 2024, 4:13PM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM